The antitumor activities of flavonoids

In Vivo

Volumn 19, Issue 5, 2005, Pages 895-910

  Kanadaswami, Chithan ^a,g   Lee, Lung Ta ^b   Lee, Ping Ping H ^c   Hwang, Jiuan Jiuan ^d   Ke, Ferng Chun ^e   Huang, Ying Tung ^f   Lee, Ming Ting ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b TOKO UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL KAOHSIUNG UNIVERSITY OF APPLIED SCIENCES   (Taiwan)

^g Advocare International   (United States)

Author keywords

Angiogenesis; Apoptosis; Flavonoids; Focal adhesion kinase; Invasion; Matrix metalloproteinase; Migration; Protein tyrosine kinase; Review

Indexed keywords

5,7,3',4' TETRAHYDROXY 3 GLYCOSYLOXYFLAVONE; ANTHOCYANIDIN; ANTINEOPLASTIC AGENT; APIGENIN; BENZOPYRAN DERIVATIVE; CATECHIN; CHROMAN DERIVATIVE; FISETIN; FLAVAN DERIVATIVE; FLAVONE; FLAVONOID; FLAVONOL; FOCAL ADHESION KINASE; GENISTEIN; ISOFLAVONE; KAEMPFEROL; LUTEOLIN; MATRIX METALLOPROTEINASE; NARINGENIN; PHENYL GROUP; PLANT MEDICINAL PRODUCT; POLYPHENOL; PROANTHOCYANIDIN; PROTEIN KINASE; PROTEIN TYROSINE KINASE; QUERCETIN; TAXIFOLIN; TOCOPHEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOGONIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASIA; ASIAN; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CELL SURFACE; COLON CANCER; DIETARY INTAKE; DRUG DESIGN; DRUG HYDROXYLATION; DRUG STRUCTURE; ENZYME INHIBITION; EXPERIMENTAL NEOPLASM; FRUIT; HERBAL MEDICINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; MITOSIS INHIBITION; NONHUMAN; PROSTATE CANCER; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TEA; TRADITIONAL MEDICINE; TUMOR VASCULARIZATION; VEGETABLE; WESTERN HEMISPHERE;

EID: 23044455268     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (178)

1. Harborne JB: Nature, distribution, and function of plant flavonoids. In: Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships. Cody V, Middleton E Jr and Harborne JB (eds.). pp. 15-24, Alan R. Liss, Inc., New York, pp. 15-24, 1986.
2. Harborne JB and Williams CA: Advances in flavonoid research since 1992. Phytochemistry 55: 481-504, 2000.
3. Herrmann K: Flavonols and flavones in food plants: a review. J Food Technol 11: 433-448, 1976.
4. Kühnau J: The flavonoids: a class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 24: 117-191, 1976.
5. Crozier A, Burns J, Aziz AA, Stewert AJ, Rabiasz HS, Jenkins GI, Edwards CA and Lean ME: Antioxidant flavonols from fruits, vegetables and beverages. Measurements and bioavailabilty. Biol Resl 33(2): 79-88, 2000.
6. Kefford JF and Chandler BV (eds.): The Chemical Constituents of Citrus Fruits. Academic Press, New York, 1970.
7. Pierpoint WS: Flavonoids in the human diet. In: Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships. Cody V, Middleton E and Harborne JB (eds.). Alan R. Liss, Inc., New York, pp. 125-140, 1986.
8. Hertog MGL, Hollman PCH and Katan MB: Content of potentially anticarcinogenic flavonoids of 28 vegetables and 9 fruits commonly consumed in the Netherlands. J Agric Food Chem 40: 2379-2383, 1992.
9. Hollman PC and Katan MB: Bioavailability and health effects of dietary flavonols in man. Arch Toxicol Suppl 20: 237-248, 1998.
10. Hertog MGL, Hollman PCH, Katan MB and Kromhout D: Intake of potentially anticarcinogenic flavonoids and their determinants in adults in the Netherlands. Nutr Cancer 20: 21-29, 1993.
11. Middleton E Jr, Kandaswami C and Theoharidis TC: The impact of plant flavonoids on mammalian biology: implications for inflammations, heart disease and cancer. Pharmacol Rev 52: 673-751, 2000.
12. Kandaswami C and Middleton E Jr: Free radical scavenging and antioxidant activity of plant flavonoids. Adv Experimen Med Biol 366: 351-376, 1994.
13. Kandaswami C and Middleton E Jr: Flavonoids as antioxidants. In: Natural Antioxidants. Shahihi E (ed.). ACS Press, Champagne, Illinois, pp. 174-203, 1997.
14. Middleton E Jr and Kandaswami C: Effects of flavonoids on immune and inflammatory cell function. Biochem Pharmaco 43: 1167-1179, 1992.
15. Middleton E Jr and Kandaswami C: The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer. In: The Flavonoids: Advances in Research. Harborne JB (eds.). Chapman and Hall, London, pp. 619-649, 1993.
16. Middleton E Jr and Kandaswami C: Potential health-promoting properties of citrus flavonoids. Food Tech 48: 115-119, 1994.
17. Castillo MH, Perkins E, Campbell JH, Doerr R, Hasset JM, Kandaswami C and Middleton E Jr: The effects of the bioflavonoids quercetin on squamous cell carcinoma of head and neck origin. Am J Surgery 158: 351-355, 1989.
18. Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ, Kandaswami C, Middleton E Jr and Lee MT: Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol 128: 999-1010, 1999.
19. Kappagoda CT, Karim M, McCormic K and Kandaswami C: Unraveling the French paradox. Chem Innov 30(9): 26-31, 2000.
20. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T and Okada H: Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 54: 1093-1100, 1991.
21. Griffths K, Denis L, Turkes A and Morton MS: Phytoestrogens and diseases of the prostate gland. Baillieres Clin Endocrinol Metab 12: 625-647, 1998.
22. Kolibaba KS and Drucker BJ: Protein kinase and inhibitor. Biochim et Biophy Acta 1333: F217-F248, 1997.
23. Stehelin D, Varmus HE, Bishop JM, and Vogt P: DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260: 170-173, 1970.
24. Powis G: Signaling pathways as targets for anticancer drug development. Pharmacol Ther 62: 57-95, 1994.
25. Levitzki A and Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995.
26. Burke TR: Protein-tyrosine kinase inhibitors. Drugs Future 17: 119-131, 1992.
27. Al-Obeidi FA, Wu JJ and Lam KS: Protein tyrosine kinase: structure, substrate specificity and drug discovery. Biopolymers 47: 197-223, 1998.
28. Soulinna EM, Buchsbaum RN and Racker E: The effect of flavonoids on aerobic glycolysis and growth of tumor cells. Cancer Res 35: 1865-1872, 1975.
29. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, Bonanno G, De Vincenzo R, Ferrandina G, Rumi C, Larocca LM and Mancuso S: Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. Br J Cancer 62: 942-946, 1990.
30. Kandaswami C, Perkins E, Soloniuk DS, Drzewiecki G and Middleton E Jr: Antiproliferative effects of citrus flavonoids on a human squamous cell carcinoma in vitro. Cancer Lett 56: 147-152, 1991.
31. Constantinou A, Kiguchi K and Huberman E: Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 50: 2618-2624, 1990.
32. Edwards JM, Raffauf RF and Quesne WL: Antineoplastic activity and cytotoxicity of flavones, isoflavones and flavanones. J Nat Prod 42: 85-91, 1979.
33. Molnar J, Beladi I, Domonkos K, Foldeak S, Boda K and Veckenstedt A: Antitumor activity of flavonoids on NK/Ly ascites tumor cells. Neoplasma 28: 11-18, 1981.
34. Lee LT, Huang YT, Hwang JJ, Lee HPP, Ke FC, Nair MP, Kandaswain C and Lee MT: Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res 22: 1615-1628, 2002.
35. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a specific inhibitor of kinases. J Biol Chem 262: 5592-5595, 1987.
36. Sato F, Matsukawa Y, Matsumoto K, Nishino H and Sakai T: Apegenin induces morphological differentiation and G2/M arrest in rat neuronal cells. Biochem Biophys Res Comm 204: 578-584, 1994.
37. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K and Uchida A: Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 54: 4952-4957, 1994.
38. Kyle E, Neckers L, Takimoto C, Curt G and Bergan R: Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 51: 193-200, 1997.
39. Weyant MJ, Carothers AM, Dannenberg AJ and Bertagnolli MM: (+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase activation in the Min/+ mouse. Cancer Res 61: 118-125, 2001.
40. Lee LT, Huang YT, Hwang JJ, Lee AYL, Ke FC, Huang CJ, Kandaswami C, Lee PPH and Lee MT: Transinactivation of the epidermal growth factor receptor tyrosine kinase and focal adhesion kinase phosphorylation by dietary flavonoids: effect on invasive potential of human carcinoma cells. Biochem Pharmacol 67: 2103-2114, 2004.
41. So FV, Guthrie N, Chambers AF, Moussa M and Carroll LL: Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 26: 167-181, 1996.
42. Nishizuka Y: Studies and perspective of protein kinase C. Science (Wash DC) 233: 305-312, 1986.
43. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (London) 334: 661-665, 1988.
44. Nishizuka Y: Protein kinase and lipid signaling for sustained cellular responses. FASEB J 9: 484-496, 1995.
45. Graziani Y, Winikoff J and Chayoth R: Regulation of cyclic AMP level and lactic acid production in Ehrlich ascites tumor cells. Biochim Biophys Acta 497: 499-506, 1977.
46. Gschwendt M, Horn F, Kittstein W and Marks F: Inhibition of the calcium- and phospholipid-dependent protein kinase activity from mouse brain cytosol by quercetin. Biochem Biophys Res Commun 117: 444-447, 1983.
47. End DW, Look RA, Shaffer NL, Balles EA and Persico FJ: Non-selective inhibition of mammalian protein kinases by flavonoids in vitro. Res Commun Chem Pathol Pharm 56: 75-86, 1987.
48. Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M and Hidaka H: Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem Pharmacol 37: 2987-2992, 1988.
49. Ferriola PC, Cody V and Middleton E: Protein kinase C inhibition by plant flavonoids, kinetic mechanism and structure-activity relationships. Biochem Pharmacol 38: 1617-1624, 1989.
50. Picq M, Dubois M, Munari-Silem Y, Prigent A-F and Pacheco H: Flavonoid modulation of protein kinase C activation. Life Sci 44: 1563-1571, 1989.
51. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H and Payrastre B: Relationship between flavonoid structure and inhibition of phosphatidyolinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53: 1649-1657, 1997.
52. Kang T and Liang N: Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells. Biochem Pharmacol 54: 1013-1018, 1997.
53. Gamet-Payrastre L, Manenti S, Gratacap MP, Tulliez J, Chap H and Payrastre B: Flavonoids and the inhibition of PKC and PI 3-kinase. Gen Pharmacol 32: 279-286, 1999.
54. Graziani Y, Erikson E and Erikson RL: The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur J Biochem 135: 583-589, 1983.
55. Alexandrakis M, Singh L, Boucher W, Letourneau R, Theoflopoulos P and Theoharides TC: Differential effects of flavonoids on inhibition of secretion and on accumulation of secretory granules in rat basophilic leukemia cells. Int J Immunopharmacol 21: 379-390, 1999.
56. Hunter T and Cooper JA: Protein tyrosine kinase. Annu Rev Biochem 54: 897-930, 1985.
57. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
58. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R and Soltoff S: Oncogenes and signal transduction. Cell 64: 281-302, 1991.
59. Bishop JM: The molecular genetics of cancer. Science 235: 305-311, 1987.
60. Linassie C, Pierre M, Peco JR and Pierre J: Mechanism of action in NIH3T3 cells of genistein, an inhibitor of EGFR receptor tyrosine activity. Biochem Pharmacol 39: 187-193, 1990.
61. Pierce JH, Ruggiero M, Fleming TP, Difiore PP, Greenberger JS, Varticovski L, Schlessinger J, Rovera G and Aaronson SA: Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. Science 239: 628-631, 1988.
62. Koch CA, Anderson D, Moran MF, Ellis C and Pawson T: SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252: 668-674, 1991.
63. Kumar V, Bustin SA and McKay LA: Transforming growth factor alpha. Cell Biol Int 19: 373-388, 1995.
64. Carpenter G and Cohen S: Epidermal growth factor. J Biol Chem 265: 7709-7712, 1990.
65. Lu Z, Jiang G, Blume-Jensen P and Hunter T: Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 21: 4016-4031, 2001.
66. Constantinou A, Kiguchi K and Huberman E: Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 50: 2618-2624, 1990.
67. Merlino GT, Xu YH, Ishii S, Clark AJ, Semba K, Yamamoto T and Pastan I: Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 224: 417-419, 1994.
68. Peterson G and Barnes S: Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 179: 661-667, 1991.
69. Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C and Nicoletti I: Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 30A: 1675-1682, 1994.
70. Yang EB, Zhang K, Cheng LY and Mack P: Butein, a specific protein kinase inhibitor. Biochem Biophys Res Commun 245: 435-438, 1998.
71. Schlaepfer DD, Hauck CR and Sieg DJ: Signaling through focal adhesion kinase. Prog Biophy Mol Biol 71: 435-478, 1999.
72. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET and Cance WG: Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55: 2752-2755, 1995.
73. Parsons JT, Martin KH, Slack JK, Taylor JM and Weed SA: Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19: 5606-5613, 2000.
74. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH and Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nature Cell Biol 2: 249-256, 2000.
75. Tamura M, Gu J, Matsumoto K, Aota SI, Parsons R and Yamada KM: Inhibition of cell migration, spreading, and focal adhesion by tumor suppressor PTEN. Science 280: 1614-1617, 1998.
76. Gu J, Tamura M, Pankov R, Danen EJK, Takino T, Matsumoto K and Yamada KM: Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 146: 389-404, 1999.
77. Caltagirone S, Rossi C, Poggi A, Ranelletti F, Natali P, Brunetti M, Aiello F and Piantelli M: Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 87(4): 595-600, 2000.
78. Mori A, Nishino C, Enoki N and Tawata S: Cytotoxicity of plant flavonoids against Hela cells. Phytochemistry 27: 1017-1020, 1988.
79. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H and Aoike A: The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett 260: 10-13, 1990.
80. Hosokawa N, Hirayoshi K, Nakai A, Hosokawa Y, Marui N, Yoshida M, Sakai T, Nishino H, Aoike A, Kawai K and Nagata K: Flavonoids inhibit the expression of heat shock proteins. Cell Struct Funct 15: 393-401, 1990.
81. Hosokawa N, Hosokawa Y, Sakai T, Yoshida M, Marui N, Nishino H, Kawai K and Aoike A: Inhibitory effect of quercetin on the synthesis of a possibly cell-cycle-related 17-kDa protein, in human colon cancer cells. Int J Cancer 45: 1119-1124, 1990.
82. Hoffman J, Ueberall F, Posch L, Maly K, Herrmann DB and Grunicke H: Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum (II) by the ether lipid analogue BN141440, an inhibitor of protein kinase C. Lipids 24: 312-317, 1989.
83. Hoffman J, Fiebig J, Winterhalter HH, Berger BR and Grunicke H: Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum (II) by quercetin. Int J Cancer 45: 536-539, 1990.
84. Kim JH, Kim SH, Alfieri AA and Young CW: Quercetin, an inhibitor of lactate transport and a hyperthermic sensitizer of HeLa cells. Cancer Res 44: 102-106, 1984.
85. Kioka M, Hosokawa N, Komano T, Hirayoshi K, Nagata K and Ueda K: Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. FEBS Lett 301: 307-309, 1992.
86. Kandaswami C, Perkins E, Soloniuk DS, Drzewiecki G and Middleton E: Ascorbic acid-enhanced antiproliferative effect of flavonoids on squamous cell carcinoma in vitro. Anticancer Drugs 4: 91-96, 1993.
87. Kandaswami C, Perkins E, Drzewiecki G, Soloniuk DS and Middleton E: Differential inhibition of proliferation of human squamous cell carcinoma, gliosarcoma and embryonic fibroblast-like lung cells in culture by plant flavonoids. Anticancer Drugs 3: 525-530, 1992.
88. Jullien M, Villaudy J, Golde A and Harel L: Inhibition by quercetin of the release of density-dependent inhibition of cell growth in RSV-transformed chicken cells. Cell Biol Int Rep 8: 939-947, 1984.
89. 3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues. Cancer Res 44: 1515-1519, 1984.
90. Carbone A, Ranelletti FO, Rinelli A, Vecchio F, Laurida L, Piantelli M and Capelli A: Type II estrogen receptors in the papillary cystic tumor of the pancreas. Am J Clin Pathol 92: 572-576, 1989.
91. Markaverich BM, Roberts RR, Alejandro MA, Johnson GA, Middleditch BS and Clark JH: Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J Steroid Biochem 30: 71-78, 1988.
92. Piantelli M, Ricci R, Larocca I-M, Rinelli A, Capelli A, Rizzo S, Scambia G and Ranelietti FO: Type II oestrogen binding sites in human colorectal carcinoma. J Clin Pathol 43: 1004-1006, 1990.
93. Mahmoud N, Carothers A, Grunberger D, Bilinski R, Churchill M, Martucci C, Newmark H and Bertagnolli M: Plant phenolics decrease in intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21: 921-927, 2000.
94. src. Naunyn-Schmiedeberg's Arch Pharmacol 217: 100-102, 1981.
95. Cunningham BDM, Threadgill MD and Hickman HA: Synthesis and evaluation of substituted flavones as inhibitors of tyrosine protein kinase. Br J Cancer 56: 207, 1987.
96. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J and Kerr DJ: Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668, 1996.
97. Singhal RL, Yeh YA, Praja N, Olah E, Sledge GW and Weber G: Quercetin down-regulates signal transduction in human breast carcinoma cells. Biochem Biophys Res Commun 208: 425-431, 1995.
98. Avila MA, Velasco JA, Cansado J and Notario V: Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res 54: 2424-2428, 1994.
99. Jankun J, Selman SH, Swiercz R and Skrzypczak-Jankun E: Why drinking green tea could prevent cancer. Nature (Lond.) 387: 561 1997.
100. Lamy S, Gingras D and Béliveau R: Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 62: 381-385, 2002.
101. Mukhtar H and Ahmad N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71(suppl): 1698S-1702S, 2000.
102. Chu D-C and Juneja LR: General chemical composition of green tea and its infusion. In: Chemistry and Applications of Green Tea. Yamamoto T, Juneja LR, Chu D-C and Kim M (eds.). CRC Press New York, pp. 13-22, 1997.
103. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimokawa R: Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.
104. Chen ZP, Schell JB, Ho CT and Chen KY: Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett 129(2): 173-179, 1998.
105. Leone M, Zhai D, Sareth S, Kitada S, Reed JC and Pellecchia M: Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 63: 8118-8121, 2003.
106. Chung JY., Huang C, Meng X, Dong Z and Yang CS: Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 59: 4610-4617, 1999.
107. Yoshida H, Ishikawa T, Hosoai H, Suzukawa M, Ayaori M, Hisada T, Sawlada S, Yonemura A, Higashi K, Ito T, Nakajima K, Yamashita T, Tomiyasu K, Nishiwaki M, Ohsuzu F and Nakamura H: Inhibitory effect of tea flavonoids on the ability of cells to oxidize low density lipoprotein. Biochem Pharmacol 58(11): 1695-703, 1999.
108. Le Marchand L: Cancer preventive effects of flavonoids - a review. Biomed Pharmacother 56(6): 296-301, 2002.
109. Messina MJ, Persky V, Setchell KDR and Barnes S: Soy intake and cancer risk; a review of the in vitro and in vivo data. Nutr Cancer 21: 114-131, 1994.
110. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM and Castanas E: Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem 78: 429-441, 2000.
111. Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeogou E, Gemetzi C, Kouroumalis E, Martin PM and Castanas E: Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 37: 105-115, 2000.
112. Adlercreutz H: Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl 201: 3-21, 1990.
113. Wang W, Tanaka Y, Han Z and Higuchi CM: Proliferative response of mammary glandular tissue to formononetin. Nutr Cancer 23: 131-140, 1995.
114. Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R and Pow-Sang J: The specific role of isoflavones in reducing prostate cancer risk. Prostate 59(2): 141-147, 2004.
115. Whyte M: ICE/CED-3 proteases in apoptosis. Trends Cell Biol 6: 245-248, 1996.
116. Vaux DL and Korsmeyer SJ: Cell death in development. Cell 96: 245-254, 1999.
117. Kidd VJ: Proteolytic activities that mediate apoptosis. Annu Rev Physiol 60: 533-573, 1998.
118. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371(6495): 346-347, 1994.
119. Jacobson MD, Weil M and Raff MC: Programmed cell death in animal development. Cell 88(3): 347-354, 1997.
120. Nagata S: Apoptosis by death factor. Cell 88(3): 355-365, 1997.
121. Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis 21(3): 485-495, 2000.
122. Traganos F, Ardelt B, Halko M, Bruno S and Darzynkiewicz Z: Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52: 6200-6208, 1992.
123. Tilly JL, Billig H, Kowalski KI and Hsueh AJ: Epidermal growth factor and basic fibroblast growth factor suppress the spontaneous onset of apoptosis in cultured rat ovarian granulosa cells and follicles by a tyrosine kinase-dependent mechanism. Mol Endocrinol 6: 1942-1950, 1992.
124. Bergamaschi G, Rosti V, Danova M, Ponchio L, Lucotti C and Cazzola M: Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines. Leukemia 7: 2012-2018, 1993.
125. Hirano T, Abe K, Gotoh M and Oka K: Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. Br J Cancer 72(6): 1380-1388, 1995.
126. Yousefi S, Green DR, Blaser K and Simon HU: Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils. Proc Natl Acad Sci (USA) 91: 10868-10872, 1994.
127. Wang IK, Lin-Shiau SY and Lin JK: Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 35(10): 1517-1525, 1999.
128. Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL and Bertagnolli MM: Phenolic antioxidants decrease intestinal tumors in an animal model of familial adenomatous. Carcinogenesis 20(2): 101-105, 1999.
129. Shukla S and Gupta S: Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog 39(2): 114-126, 2004.
130. Ikezoe T, Chen SS, Heber D, Taguchi H and Koeffler HP: Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49(4): 285-292, 2001.
131. Liang YC, Lin-Shiau SY, Chen CF and Lin JK: Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 67(1): 55-65, 1997.
132. Ishikawa Y and Kitamura M: Bioflavonoid quercetin inhibits mitosis and apoptosis of glomerular cells in vitro and in vivo. Biochem Biophys Res Commun 279(2): 629-634, 2000.
133. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
134. Schneider MR and Schirner M: Antimetastatic prostacyclin analog. Drugs Future 18: 29-48, 1993.
135. Liabakk NB, Talbot I, Smith RA, Wilkinson K and Balkwill F: Matrix metalloproteinases 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56: 190-196, 1996.
136. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F: Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369, 1993.
137. Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-2091, 1993.
138. Naylor MS, Stamp GW, Davies BD and Balkwill FR: Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 58: 50-56, 1994.
139. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL and Rees RC: Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69: 177-182, 1994.
140. Lin SW, Lee MT, Ke FC, Lee PP, Huang CJ, Ip MM, Chen L and Hwang JJ: TGFβ1 stimulates the secretion of matrix metalloproteinase MMP inhibitor BB3103. Clin Exp Meta 18: 493-499, 2001.
141. Benaud C, Dickson RB and Thompson EW: Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 50: 97-116, 1998.
142. Hua J and Muschel R: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56: 5279-5284, 1996.
143. Matrisian LM: Metalloproteinases and their inhibitors in matrix remolding. Trends Genet 6: 121-125, 1990.
144. Liotta LA: Cancer cell invasion and metastasis. Medicine Sci Am 266: 54-59, 62-63, 1992.
145. Rhee JS and Coussens LM: RECKing MMP function: implications for cancer development. Trends Cell Biol 12(5): 209-211, 2002.
146. Wagenaar-Miller RA, Gorden L and Matrisian LM: Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 23(1-2): 119-135, 2004.
147. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89(17): 1260-1270, 1997.
148. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3): 161-174, 2002.
149. Beattie GJ and Smyth JF: Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 4(8): 1899-1902, 1998.
150. Caputo CB, Wolanin DJ, Roberts RA, Sygowski LA, Patton SP, Caccese RG, Shaw A and DiPasquale G: Proteoglycan degradation by a chondrocyte metalloprotease: effects of synthetic protease inhibitors. Biochem Pharmacol 36(7): 995-1002, 1987.
151. Lin N, Sato T, Takayama Y, Mimaki Y, Sashida Y, Yano M and Ito A: Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol 65(12): 2065-2071, 2003.
152. Kim MH: Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem 89(3): 529-538, 2003.
153. Moon SY, Cho GO, Jung SY, Gal SW, Kwon TY, Lee YC, Madamanchi NR and Kim CH: Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle regulation, and matrix metalloproteinase-9. Biochem Biophys Res Commun 301(4): 1069-1078, 2003.
154. Zhang XM, Huang SP and Xu Q: Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway. Cancer Chemother Pharmacol 53(1): 82-88, 2004.
155. Shao ZM, Wu J, Shen ZZ and Barsky SH: Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58(21): 4851-4857, 1998.
156. Shao ZM, Wu J, Shen ZZ and Barsky SH: Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Res 18(3A): 1435-1439, 1998.
157. Magee PJ, McGlynn H and Rowland IR: Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett 208(1): 35-41, 2004.
158. Ende C and Gebhardt R: Inhibition of matrix metalloproteinase-2 and -9 activities by selected flavonoids. Planta Med 70(10): 1006-1008, 2004.
159. Tate P, God J, Bibb R, Lu Q and Larcom LL: Inhibition of metalloproteinase activity by fruit extracts. Cancer Lett 212(2): 153-158, 2004.
160. Demeule M, Brossard M, Page M, Gingras D and Beliveau R: Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 1478(1): 51-60, 2000.
161. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R and Albini A: Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 91(4): 822-832, 2001.
162. Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R and Albini A: Tumor invasion: molecular shears blunted by green tea. Nat Med 5(11): 1216, 1999.
163. Scholar EM and Toews ML: Inhibition of invasion of murine mammary carcinoma cells by the tyrosine kinase inhibitor genistein. Cancer Lett 87(2): 159-162, 1994.
164. Zhang L, Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C and Hung MC: Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16(22): 2855-2863, 1998.
165. Bracke ME, Castronovo V, Van Cauwenberge RM, Coopman P, Vakaet L Jr, Strojny P, Foidart JM and Mareel MM: The anti-invasive flavonoid (+)-catechin binds to laminin and abrogates the effect of laminin on cell morphology and adhesion. Exp Cell Res 173(1): 193-205, 1987.
166. Bracke ME, Vyncke BM, Van Larebeke NA, Bruyneel EA, De Bruyne GK, De Pestel GH, De Coster WJ, Espeel MF and Mareel MM: The flavonoid tangeretin inhibits invasion of MO4 mouse cells into embryonic chick heart in vitro. Clin Exp Metastasis. 7(3): 283-300, 1989.
167. Parmar VS, Jain R, Sharma SK, Vardhan A, Jha A, Taneja P, Singh S, Vyncke BM, Bracke ME and Mareel MM: Anti-invasive activity of 3,7-dimethoxyflavone in vitro. J Pharm Sci 83(9): 1217-1221, 1994.
168. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R and Schweigerer L: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci (USA) 90(7): 2690-2694, 1993.
169. Fotis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R and Schweigerer L: Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 57: 2916-2921, 1997.
170. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C and Fotsis T: Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res 64: 7936-7946, 2004.
171. Kessler DA, Langer RS, Pless NA and Folkman J: Mast cells and tumor angiogenesis. Int J Cancer 18(5): 703-709, 1976.
172. Poole TJ and Zetter BR: Stimulation of rat peritoneal mast cell migration by tumor-derived peptides. Cancer Res 43: 5857-5861, 1983.
173. Scott KG: The mast cell, its amines, and tumor growth in rodents and man. Ann NY Acad Sci 103: 285-312, 1963.
174. Theoharides TC: Neuroimmunology of tumor growth: the role of mast cells. Int J Immunopathol Pharmacol 1: 89-98, 1988.
175. Anné S, Agarwal R, Nair MP, Schwartz SA, Ballow M, Kandaswami C and Middleton E Jr: Inhibition of endotoxin-induced expression of intercellular adhesion molecule-1 and of leukocyte adhesion to endothelial cells by the plant flavonoid quercetin. J Allergy Clin Immunol 93: 276, 1994.
176. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D and Murphy GF: Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci (USA) 88(10): 4220-4224, 1991.
177. Gerritsen ME, Carley WW, Ranges GE, Shen C-P, Phan SA, Ligon GF and Perry CA: Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol 147: 278-292, 1995.
178. Myoung H Kim: Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem 89(3): 529-538, 2003.